ABOUT US PRODUCT PIPELINE TECHNOLOGY PARTNERS  INVESTORS NEWS  CAREERS       Home  Contact  Search  Site Map   Corporate Profile  Financial Information  Corporate Governance  Reports & Presentations  Press Releases  IR Calendar & Events  Shareholder Services Sign up for messages to be conveniently delivered to your email whenever new company information is posted. Sign up here to receive Crucell's newsletter. Dutch    German                                 2006 |2005 | 2004 | 2003 | 2002 | 2001 | 2000   24 Dec 2002 Centocor returns rights to anti-CD46 antibody to Crucell 23 Dec 2002 Crucell Expects Charge Related to Impairment of Goodwill 20 Dec 2002 Cambridge Antibody Technology and Crucell Settle Patent Dispute 19 Dec 2002 Biotech Alliance of DSM Biologics and Crucell - for faster preparation of new medicines at lower cost 05 Nov 2002 Crucell Appoints Director Corporate Communications 14 Oct 2002 Crucell and the US National Institutes of Health Sign Contract for Production of Ebola, Marburg and Lassa Vaccines for Use in Human Clinical Trials 14 Oct 2002 Crucell Revenues EUR 2.0 million in Third Quarter 2002 04 Oct 2002 Invitation Conference Call Q3 Results 2002 03 Oct 2002 Crucell to Webcast Presentation at UBS Warburg Global Life Sciences Conference 01 Oct 2002 Crucell and Applied Molecular Evolution Sign PER.C6(TM) Antibody Production Agreement 09 Sep 2002 Crucell announces management changes 05 Sep 2002 Crucell Signs PER.C6(TM) Agreement with NatImmune 16 Aug 2002 Crucell and Johns Hopkins Announce Research Agreement for Antibodies against LCH 12 Aug 2002 Crucell Signs PER.C6(TM) Licensing Agreement with GenVec 07 Aug 2002 Crucell and NIH Extend Ebola Vaccine Agreement to include Marburg and Lassa Vaccines 19 Jul 2002 Crucell Appoints Dr. Jaap Goudsmit to Executive Committee 15 Jul 2002 Crucell Increases Second Quarter 2002 Revenues by 131% 08 Jul 2002 Crucell maintains earlier profit statements 03 Jul 2002 Crucell and Genexine Announce Agreement 04 Jun 2002 Crucell to Webcast Presentation at the Needham & Company Biotech Conference 29 May 2002 Crucell signs PER.C6TM license with MedImmune 16 May 2002 Crucell and NIH to develop ebola vaccine 15 Apr 2002 Crucell's first quarter 2002 revenues increase 135% 10 Apr 2002 Rhein Biotech and Crucell enter into PER.C6 License agreement 05 Mar 2002 Crucell: preliminary Phase I data of PER.C6-derived HIV vaccine encouraging 04 Mar 2002 Crucell spin-out Galapagos Genomics NV to complete a private placement 01 Feb 2002 First milestone achieved in Centocor-Crucell agreement for CD46 human antibodies against cancer 24 Jan 2002 Invitation Conference Call Annual Results 23 Jan 2002 Crucell and Innogenetics announce PER.C6 deal for the development and manufacturing of antibodies 17 Jan 2002 Crucell appoints VP Development and Regulatory Affairs 15 Jan 2002 Lexigen signs on as Crucell's 19th PER.C6 licensee 10 Jan 2002 PER.C6 manufacturing services available in United States   Home    Contact    Search    Site Map
© Crucell 2006 | Disclaimer